A patient suffered a critical overdose due to an error in the additive manufacturing of a personalized drug. The tablet, designed for controlled release using ZipDose technology, released the active ingredient instantaneously. The investigation focused on the internal architecture of the pill, using micro-CT to scan the structure and determine if a defect in the porosity of the internal mesh was the cause of the catastrophic failure.
Micro-CT and simulation: the digital autopsy of the tablet 🧬
The analysis pipeline began with a micro-CT scan of the defective tablet. The volumetric data was processed in VGSTUDIO MAX to perform a micro-structure analysis, revealing areas of irregular porosity that differed from the original design. This real geometry was exported to Materialise Mimics for precise segmentation of the polymer matrix. Finally, a dissolution simulation was run in Ansys, where the model with defective porosity showed immediate release kinetics, in contrast to the expected sustained release curve. The failure was attributed to a variation in printing parameters that collapsed the internal mesh.
Non-optional quality control in the 3D pharmacy 🔬
This case underscores an uncomfortable truth for 3D biomedicine: dose personalization introduces a unique manufacturing risk. Unlike traditional pressed tablets, the internal structure of a printed drug dictates its efficacy and safety. The integration of micro-CT and simulation is not a luxury, but a regulatory necessity to validate each batch. Without these controls, the promise of personalized medicine can become a systemic danger to the patient.
Since uncontrolled porosity in ZipDose additive manufacturing can alter the drug release kinetics and cause an overdose, which printing parameters are most critical to ensure the structural homogeneity of the tablet and prevent similar hidden failures?
(PS: and if the printed organ doesn't beat, you can always add a little motor... just kidding!)